Selank (sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide derived from the naturally occurring immunomodulatory peptide tuftsin, extended with a Pro-Gly-Pro stabilizing sequence to dramatically extend the molecule’s plasma half-life. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and approved in Russia since 2009, it remains one of the most extensively documented anxiolytic peptides outside the benzodiazepine class and a staple reference compound in short-peptide CNS research.
Researchers buy Selank to investigate an unusual anxiolytic profile: it modulates GABA-A receptor function in a manner analogous to benzodiazepines, yet preclinical models consistently show no sedation, no tolerance development, no cognitive impairment, and no physical dependence after chronic dosing. For a deeper overview, see our Selank research guide and related Semax vs Selank comparison.
Because Selank crosses the blood-brain barrier efficiently and tolerates intranasal, subcutaneous, and intraperitoneal delivery in animal models, it has become a practical tool peptide for groups studying stress-response biology, learning and memory, neuroimmune crosstalk, and novel anxiolytic mechanisms without the confounders that benzodiazepine comparators introduce.
Detailed Mechanism of Action
Selank exerts its anxiolytic effects through a multi-target mechanism that distinguishes it sharply from classical benzodiazepine anxiolytics. Researchers who buy Selank most often investigate four converging pathways: GABAergic modulation, BDNF-driven neuroplasticity, monoaminergic balance, and enkephalin stabilization. Each pathway contributes to the observed anxiolytic-nootropic hybrid profile without the sedation or dependence liability of traditional GABAergic compounds.
The GABA-A axis is the most well-characterized target. Selank enhances receptor sensitivity and modulates GABAergic neurotransmission, producing anxiolytic effects comparable to benzodiazepines in elevated plus maze, open field, and Vogel conflict paradigms — yet without the locomotor suppression or memory impairment benchmarks seen with diazepam controls. The current working hypothesis in the literature is that Selank acts as a positive allosteric modulator with subunit preferences that differ from diazepam, sparing the sedative-hypnotic circuitry while still exerting anxiolysis.
Selank also drives robust upregulation of brain-derived neurotrophic factor (BDNF) in the hippocampus and prefrontal cortex — the same structures most implicated in anxiety, chronic stress, and declarative memory. BDNF is central to synaptic plasticity, long-term potentiation, and memory consolidation, which is why investigators who buy Selank frequently pair it with learning and cognitive-resilience assays such as Morris water maze, novel object recognition, and passive avoidance.
Parallel effects on serotonin metabolism, dopamine turnover, and enkephalin-degrading enzyme inhibition complete the profile. By inhibiting the breakdown of endogenous opioid peptides, Selank prolongs the activity of stress-buffering signaling systems without engaging opioid receptors directly. As a tuftsin-derived analog, Selank additionally modulates cytokines and immune-cell activity, bridging the neuroimmune axis — a feature detailed in our immune peptides overview.
Gene-expression studies add a final layer: Selank administration alters transcription of genes involved in neurotrophic signaling, inflammation, and monoaminergic metabolism within hours of a single dose. This rapid, broad transcriptional response helps explain why a short heptapeptide with a brief plasma half-life can produce measurable behavioral and biochemical changes that persist well beyond the drug’s circulating window.
Published Research
Selank has an unusually deep research record for a non-Western peptide. Semenova and colleagues (2007, Pharmacology Biochemistry and Behavior) demonstrated non-sedating anxiolytic activity comparable to medazepam in rodent conflict and exploratory-behavior paradigms, establishing the core pharmacological signature that still anchors Selank research today. Uchakina and colleagues (2008, Bulletin of Experimental Biology and Medicine) characterized immunomodulatory effects, showing dose-dependent cytokine shifts consistent with tuftsin ancestry and reinforcing the neuroimmune framing of the peptide.
Follow-on work examined BDNF upregulation, serotonin metabolite ratios, and gene-expression changes in the hippocampus after intranasal administration — the route most commonly used in clinical Selank research due to rapid CNS penetration. Investigators who buy Selank for neuropharmacology workflows typically cite this literature alongside PubMed indexed Selank studies and complementary PMC full-text articles to map the current evidence base.
Comparative studies against benzodiazepines, buspirone, and the related peptide Semax continue to refine the picture: a short-chain peptide with benzodiazepine-like efficacy, SSRI-like mood effects, and nootropic BDNF signaling — all without the cognitive cost that typically accompanies GABAergic drugs. Human pharmacokinetic and EEG studies from Russian clinical groups further describe rapid CNS effects after intranasal dosing, with changes in cortical rhythms observable within 30 minutes.
More recent literature has explored Selank’s interaction with stress-response transcription factors, its influence on HPA-axis readouts like corticosterone, and its utility as a pharmacological probe in depression- and PTSD-adjacent animal models. Combined, this body of work makes Selank one of the best-documented non-benzodiazepine GABAergic tools currently available to research laboratories.
Selank vs Alternatives
| Feature |
Selank |
Semax |
Benzodiazepines |
| Primary profile |
Anxiolytic + nootropic |
Nootropic + neuroprotective |
Anxiolytic, sedative |
| Primary target |
GABA-A modulation, BDNF |
BDNF/NGF, melanocortin |
GABA-A allosteric |
| Sedation |
None reported |
None |
Significant |
| Tolerance / dependence |
Not observed preclinically |
Not observed |
Well documented |
| Cognitive effect |
Neutral to pro-cognitive |
Pro-cognitive |
Impairment |
| Typical research route |
Intranasal / SC |
Intranasal / SC |
Oral |
| Half-life |
Short; repeated dosing in studies |
Short |
Varies widely |
| Research classification |
Research peptide |
Research peptide |
Scheduled drugs |
Reconstitution & Handling
Selank ships as a lyophilized powder and must be reconstituted with bacteriostatic water prior to use in any research protocol. Typical reconstitution uses 2 mL or 3 mL of bacteriostatic water per vial depending on the target concentration in the study design. Swirl gently — never shake — and allow the solution to equilibrate for 30 seconds before drawing. Detailed protocols are available in our peptide reconstitution guide, and the peptide dosage calculator simplifies volume-per-dose math for any vial size.
Laboratories that buy Selank for repeated-dose paradigms often prepare a single reconstituted vial and aliquot across the study to minimize freeze-thaw cycles. Keep workspaces sterile, use fresh needles for each draw, and protect the peptide from direct light during handling. If intranasal delivery is part of the study design, researchers typically transfer an aliquot to a calibrated nasal spray bottle, recording dead volume and per-spray dose for reproducibility.
Bacteriostatic water is the standard diluent because its 0.9% benzyl alcohol content suppresses microbial growth across the 30-day refrigerated shelf window. For a background primer, see our explainer on what bacteriostatic water is and why it is used in peptide reconstitution.
Storage & Stability
After you buy Selank, store the lyophilized vial below −20°C for long-term stability; the peptide remains stable for months when kept dry, cold, and protected from light. Short-term refrigeration at 2–8°C is acceptable for several weeks if freezer space is limited, but freezer storage is preferred for any vial that will not be reconstituted within the month.
Once you buy Selank and reconstitute it, refrigerate at 2–8°C and use within approximately 30 days. Avoid repeated freeze-thaw cycles of reconstituted solution, as peptide bonds are sensitive to physical stress and temperature fluctuations. Laboratories typically aliquot the reconstituted vial into single-use tubes and freeze the aliquots at −20°C, thawing one at a time to preserve integrity. Our peptide storage guide and degradation indicators article cover visual cues such as cloudiness, particulate formation, or discoloration that signal loss of peptide integrity.
Certificate of Analysis
Every time you buy Selank, the order includes a batch-specific COA documenting HPLC purity, identity confirmation via mass spectrometry, physical appearance, and lot-specific testing dates. Teams that buy Selank for publication-grade work typically archive the COA alongside their lab notebooks and raw data so that any reviewer can trace material provenance. If you have never interpreted a peptide COA, our COA reading guide walks through each section line by line and explains how to convert relative peak areas into a defensible purity percentage.
For every lot shipped when customers buy Selank, mass spectrometry identity confirmation verifies that the observed molecular ion matches the theoretical mass of the Thr-Lys-Pro-Arg-Pro-Gly-Pro sequence within the expected tolerance, ruling out truncation products or incorrect sequences. HPLC purity is then reported as the area percentage of the main peak relative to total peak area, with a typical acceptance threshold of ≥98% and PSPeptides product tolerance set at ≥99%.
Why Researchers Choose PSPeptides
- US Manufactured: Synthesized and filled in US facilities under strict QC procedures.
- Third-Party Tested: Independent HPLC and mass spectrometry on every batch with COA included.
- Fast Shipping: Free UPS 2nd Day Air over $150, same-day dispatch before 2 PM EST.
- Flexible Payments: Credit cards, Afterpay, Klarna, Apple Pay, Google Pay.
- 7-Day Support: Email, phone, or text — responsive researcher support all week.
- Deep Catalog: Matched analogs like Semax, plus supplies such as bacteriostatic water and sterile syringes.
Chronic Dosing Models and Tolerance Assessment
A defining feature of Selank in preclinical work is the apparent absence of tolerance after prolonged administration. Groups that buy Selank for chronic dosing paradigms frequently run 14- to 30-day protocols with daily intranasal or subcutaneous delivery and track behavioral endpoints at baseline, mid-study, and terminal timepoints. Unlike benzodiazepines — where the anxiolytic effect typically attenuates within a week of daily dosing — Selank maintains stable performance on elevated plus maze and light-dark box metrics across extended timelines.
Withdrawal markers are equally informative. Abrupt discontinuation of benzodiazepines in rodents produces measurable rebound anxiety, irritability, and sometimes seizures in high-dose groups. Buy Selank data from published models shows discontinuation has not produced analogous withdrawal signs, which is one reason investigators who buy Selank cite it as a mechanistic probe for dissecting which features of GABA-A engagement drive the dependence phenotype versus the therapeutic anxiolytic effect.
When labs buy Selank for tolerance assessment, protocols typically pair behavioral testing with receptor-binding assays and transcriptomic snapshots of hippocampus, prefrontal cortex, and amygdala. These studies have repeatedly failed to detect downregulation of GABA-A receptor density or desensitization patterns after chronic Selank exposure — a contrast to the well-documented receptor adaptations seen with chronic benzodiazepine dosing.
Pharmacokinetics and Delivery Routes
Selank is rapidly absorbed and distributed after intranasal, subcutaneous, and intraperitoneal administration. For labs that buy Selank for clinical-translational workflows, intranasal delivery is the dominant route in Russian clinical research because the nasal mucosa offers direct access to the CNS via olfactory and trigeminal pathways, bypassing first-pass metabolism entirely. EEG and behavioral effects are typically measurable within 20 to 30 minutes of an intranasal dose, and peak pharmacodynamic activity aligns with these rapid onset profiles despite a modest circulating half-life.
Subcutaneous delivery of Selank material is the workhorse for rodent preclinical studies, offering reproducible dosing without the inter-animal variability that nasal delivery introduces in a rodent housing environment. Intraperitoneal delivery is occasionally used but less frequently because it changes the absorption kinetics. Laboratories that buy Selank should select the route that best matches their study model, IACUC requirements, and the published literature they are benchmarking against.
Because the peptide’s behavioral effects outlast the circulating drug, pharmacokinetic profiling alone underestimates the pharmacodynamic window. This dissociation is characteristic of peptides that drive gene-expression changes: a brief plasma exposure can trigger a cascade of transcriptional effects that persist for hours to days. Researchers building dosing schedules typically rely on pharmacodynamic endpoints — behavioral tests, EEG, or BDNF measurements — rather than plasma-concentration curves alone.
Combination Research: Selank and Semax
One of the most active research threads involving Selank is the combined Selank + Semax paradigm. Because Semax is nootropic and neuroprotective while Selank is anxiolytic and nootropic, groups that buy Selank alongside Semax the two peptides cover overlapping but distinct CNS territory. Laboratories that buy Selank alongside Semax typically run parallel arms to tease apart which endpoints respond to each peptide individually versus which respond additively or synergistically to the combination.
Teams that buy Selank run cognitive paradigms such as novel object recognition, Morris water maze, passive avoidance — often show additive benefits from the combination, consistent with the hypothesis that BDNF upregulation is a shared downstream event. Anxiety paradigms where teams buy Selank show the Selank-dominant signature, which is expected given Semax’s minimal anxiolytic profile. Neurochemical readouts add another layer: Selank modulates GABAergic and serotonergic systems more strongly, while Semax drives BDNF/NGF signaling and melanocortin engagement more directly.
Our Semax vs Selank comparison and peptide stacking guide outline typical co-administration designs, including staggered vs simultaneous dosing, route selection, and statistical approaches for decomposing main effects from interaction effects in factorial designs.
Quality Controls and Batch Traceability
PSPeptides Selank is produced under a QC framework designed specifically for research peptides. Each production lot is assigned a unique batch identifier that ties back to the synthesis record, the identity confirmation mass spectrum, the HPLC purity trace, and the fill record. The COA included with every order references this batch identifier, so teams that buy Selank can cross-reference any vial to its full production lineage — essential for publication and for any subsequent inquiry from reviewers or collaborators.
Third-party HPLC and mass spectrometry are performed independently of the manufacturing facility, which means the purity and identity data reaching the customer have not been self-certified by the producer. This separation of testing is a foundational expectation in research-grade peptide supply and is a key reason laboratories that have been burned by inconsistent vendors migrate to third-party-tested suppliers.
When researchers buy Selank from PSPeptides, vials are sealed, labeled, and packaged to withstand standard 2-day ground or air freight without temperature excursions severe enough to compromise lyophilized peptide integrity. For long-haul international shipments or summer shipping windows in hot climates, customers can request thermal packaging; for most domestic US orders, standard packaging is sufficient for the lyophilized form factor. For a broader discussion of supplier evaluation criteria, see our guide to choosing a research peptide supplier.
Common Pitfalls When Working With Selank
Three issues account for most of the avoidable problems we see when researchers buy Selank and researchers encounter when they buy Selank for the first time. First, over-vigorous reconstitution: shaking a freshly reconstituted vial can shear the peptide and introduce foam that traps air and reduces drawable volume. The correct technique is to add diluent along the vial wall, swirl gently, and wait for full dissolution.
Second, temperature mismanagement: leaving reconstituted Selank at room temperature for extended periods, or cycling it through multiple freeze-thaws, accelerates degradation even with bacteriostatic water present. The aliquot-and-freeze workflow solves this problem with minimal overhead.
Third, route mismatch with the target literature. A study benchmarking against intranasal Russian clinical data should not use intraperitoneal delivery in rodents without justification, because absorption kinetics and CNS-access profiles differ meaningfully. Researchers who buy Selank for translational work should align the route with the literature they intend to compare against and document any deviations explicitly in their methods.
Frequently Asked Questions
Is Selank the same as Semax?
No. Both are Russian-developed short-chain peptides, but Selank is tuftsin-derived with an anxiolytic-forward GABAergic profile, while Semax is ACTH-derived and primarily nootropic and neuroprotective. Many researchers who buy Selank also run Semax arms for comparative cognition and mood endpoints within the same study.
Why is Selank studied without the sedation seen with benzodiazepines?
Preclinical data suggest Selank modulates GABA-A receptor subtypes differently than classical benzodiazepines, producing anxiolysis without the locomotor suppression or memory impairment that benzodiazepines typically cause. The exact subunit selectivity remains an active research area and a primary reason investigators buy Selank for mechanistic studies.
What route of administration do most Selank studies use?
Intranasal administration dominates the clinical Selank literature due to rapid CNS penetration; subcutaneous administration is common in preclinical rodent work. Researchers who buy Selank should choose the route that matches their study model and IACUC protocol, recording per-dose volumes and timing carefully.
How should I reconstitute Selank for a research protocol?
Use bacteriostatic water, typically 2–3 mL per vial based on the target concentration. Swirl gently, refrigerate, and review our reconstitution guide and dosage calculator for exact volume-per-concentration math. For repeated-dose studies, aliquot and freeze to minimize freeze-thaw cycles.
How is Selank different from everyday anxiolytics in research use?
Classical anxiolytics like benzodiazepines engage GABA-A broadly and cause sedation, memory impairment, and dependence. Selank engages GABAergic signaling selectively and co-modulates BDNF, serotonin, and enkephalin systems, yielding anxiolysis without the classic liabilities — which makes it a uniquely clean probe for anxiolytic-nootropic research.
Related Resources
All PSPeptides products are sold exclusively for laboratory and research use. Not intended for human consumption.
US Made & Shipped
